Initial experiences with subcutaneous recombinant human hyaluronidase

Journal of Palliative Medicine

Volumn 10, Issue 4, 2007, Pages 861-864

  Pirrello, Rosene D ^a,b   Chen, Christina Ting ^b   Thomas, Sandra H ^a  

^a San Diego Hospice and Palliative Care   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; HYALURONOGLUCOSAMINIDASE; PH 20 PROTEIN; PH-20 PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DEHYDRATION; FEMALE; HOSPICE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEDICAL AUDIT; METABOLISM; MIDDLE AGED; PROTEIN ENGINEERING; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CELL ADHESION MOLECULES; DEHYDRATION; FEMALE; HOSPICES; HUMANS; HYALURONOGLUCOSAMINIDASE; INFUSIONS, INTRAVENOUS; MALE; MEDICAL AUDIT; MIDDLE AGED; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 34848884859     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2007.0037     Document Type: Article

References (18)

1. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114: 230-241.
2. Chain E, Duthie E: Identity of hyaluronidase as spreading factor. Br J Exp Pathol 1940;21.
3. Myers K: Biological significance of hyaluronic acid and hyaluronidase. Physiol Rev 1947;27.
4. Hechter O: The clinical use of hyaluronidase in hypodermoclysis. J Pediatr 1947;30:645-656.
5. Lipschitz S, Campbell AJ, Roberts MS, Wanwimolruk S, McQueen EG, McQueen M, Firth LA: Subcutaneous fluid administration in elderly subjects: Validation of an underused technique. J Am Geriatr Soc 1991;39:6-9.
6. Webb W: Effect of hyaluronidase on rate of absorption of subcutaneous fluids. Arch Surg 1952:770-773.
7. Constans T, Dutertre JP, Froge E: Hypodermoclysis in dehydrated elderly patients: Local effects with and without hyaluronidase. J Palliat Care 1991;7:10-12.
8. Lanuke K, Fainsinger RL, DeMoissac D: Hydration management at the end of life. J Palliat Med 2004;7:257-263.
9. Fainsinger RL, MacEachern T, Miller MJ, Bruera E, Spachynski K, Kuehn N, Hanson J: The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symptom Manage 1994;9:298-302.
10. Dalal S, Bruera E: Dehydration in cancer patients: To treat or not to treat. J Support Oncol 2004;2:467-479, 483.
11. Bruera E, Neumann CM, Pituskin E, Calder K, Hanson J: A randomized controlled trial of local injections of hyaluronidase versus placebo in cancer patients receiving subcutaneous hydration. Ann Oncol 1999;10:1255-1258.
12. Thomas JR, Yocum RC, Haller MF, von Gunten CF: Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: The INFUSE-LR study. J Palliat Med (accepted for publication).
13. Thomas JR, Yocum RC, Haller MF, von Gunten CF: Can human recombinant hyaluronidase enhance the absorption of subcutaneously administered morphine? The INFUSE-morphine study. Abstract # 5086 at 2007 AAHPM Meeting in Salt Lake City 2007.
14. Baxter Healthcare Corporation. Hylenex recombinant (hyaluronidase human injection) 2006. United States prescribing information.
15. Ebo DG, Goossens S, Opsomer F, Bridts CH, Stevens WJ: Flow-assisted diagnosis of anaphylaxis to hyaluronidase. Allergy 2005;60:1333-1334.
16. Schwartzman J: Hyaluronidase: A review of its therapeutic use in pediatrics. J Pediatr 1951;39:491-502.
17. Thomas JR, Kronenberg R, Cox MC, Naco GC, Wallace M, Von Gunten CF: Intravenous lidocaine relieves severe pain: Results of an inpatient hospice chart review. J Palliat Med 2004;7:660-667.
18. Ferrini R: Parenteral lidocaine for severe intractable pain in six hospice patients continued at home. J Palliat Med 2000;3:193-200.